Tweeter button Delicious button Digg button Stumbleupon button
Fatty Liver Disease | Research And Markets: Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline Review, H2 2013

DUBLIN–(BUSINESS WIRE)–

Research and Markets ( ) has announced the addition of the “Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline Review, H2 2013″ report to their offering.

This report provides information on the therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD).

Scope

– A snapshot of the global therapeutic scenario for Non Alcoholic Fatty Liver Disease (NAFLD).


– A review of the Non Alcoholic Fatty Liver Disease (NAFLD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

– Coverage of products based on various stages of development ranging from discovery till registration stages.

– A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

– Coverage of the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline on the basis of route of administration and molecule type.

– Key discontinued pipeline projects.

– News and deals relating to the products.

Reasons to Buy

– Identify and understand important and diverse types of therapeutics under development for Non Alcoholic Fatty Liver


Click here to view rest of article from original site


Facebook Twitter Email

Important Disclaimer: Article Comments provided are for general information purposes only and are not intended to substitute for informed professional medical, psychological, tax, accounting, legal, investment, or any other professional advice. We expressly disclaim liability for any product, manufacturer, distributor, service or service provider mentioned or any opinion expressed in these comments or anywhere else within the site. Lastly, we do not endorse any article or comment. Use at your own risk.